ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy
Status:
Not yet recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
In this research study, is combining a new treatment acalabrutinib with a standard treatment,
rituximab or other CD20 antibody, to determine whether this combination is safe and effective
for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined
significance ( IgM MGUS) or Waldenström macroglobulinemia WM related neuropathies.
The names of the study drugs involved in this study are/is:
- Acalabrutinib
- Rituximab or similar CD20 antibody